基本信息
浏览量:20
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
My main research interests are gastrointestinal oncology, early phase clinical trials and translational research. I pioneered Hong Kong Liver Cancer classification, which has revolutionized the treatment algorithm of liver cancer patients. Moreover, I am actively involved in cancer drug development, especially in the field of caner immunotherapy. I have led few global ground-breaking immunotherapy trials for liver cancer and some of these trials led to global drug approval for advanced hepatocellular carcinoma patients. I have published more than 140 peer-review publications with first author articles in various leading oncology journals, namely Lancet, JAMA Oncology, Gastroenterology, and Journal of Hepatology. My latest H index is 49 with over 10000 citations in the literature. I am the recipient of projects funded by, Theme-based Research Scheme and General Research Fund, University Grant Committee in Hong Kong. I also received Innovation and Technology Fund and Hong Kong Health and Research Fund as well.
Internationally, I am currently the faculty member of the European Society of Medical Oncology (ESMO) in gastrointestinal cancer and a member of The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. I am also vice president of Asia Pacific Neuroendocrine Tumour Society, council member of The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association and International Faculty Board Member of International Association of Surgeons Gastroenterologist and Oncologists and member of many international professional societies. Previously, I was an international member of US NCI Hepatobiliary Task Force. In Hong Kong, I am a general secretary of Hong Kong Liver Cancer Foundation and council member of Hong Kong Sustainable Council.
Internationally, I am currently the faculty member of the European Society of Medical Oncology (ESMO) in gastrointestinal cancer and a member of The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. I am also vice president of Asia Pacific Neuroendocrine Tumour Society, council member of The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association and International Faculty Board Member of International Association of Surgeons Gastroenterologist and Oncologists and member of many international professional societies. Previously, I was an international member of US NCI Hepatobiliary Task Force. In Hong Kong, I am a general secretary of Hong Kong Liver Cancer Foundation and council member of Hong Kong Sustainable Council.
研究兴趣
论文共 223 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The lancet. Gastroenterology & hepatologyno. 4 (2024): 310-322
Sarwan Bishnoi,Dusan Kotasek,Morteza Aghmesheh,Thomas Yau,Rasha Cosman,Amy Prawira,Maggie Moore, Stephen L. Chan,Andrew Mant,Richard Eek, Robert Zielinski,Rila Su,
Cancerno. 11 (2024): 1991-2002
Tan-To Cheung,Daniel Wai-Hung Ho,Shirley Xueying Lyu,Qingyang Zhang,Yu-Man Tsui, Tiffany Ching-Yun Yu,Karen Man-Fong Sze,Joyce Man-Fong Lee,Vince Wing-hang Lau, Edward Yin-Lun Chu,Simon Hing-Yin Tsang,Wong-Hoi She,
LIVER CANCERno. 1 (2024): 70-88
Benjamin Koh,Darren Jun Hao Tan,Wen Hui Lim, Jeffrey S. L. Wong,Cheng Han Ng,Kai En Chan,Meng Wang,Wei Peng Yong,Yock Young Dan,Louis Z. Wang, Nigel Tan,Mark Muthiah,
Oncoimmunologyno. 1 (2023): 2214478
Changhoon Yoo,Richard S. Finn, Heinz-Josef Klu Spacing Diaeresis Mpen,Robin Kate Kelley,Arndt Vogel,Junji Furuse,Zhenggang Ren,Thomas Yau,Stephen Lam Chan,Masato Ozaka,Sang Cheul Oh,Shanzhi Gu,
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 4003-4003
加载更多
作者统计
#Papers: 226
#Citation: 16556
H-Index: 54
G-Index: 127
Sociability: 7
Diversity: 4
Activity: 163
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn